Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Cytotoxic treatment of ad… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Cytotoxic treatment of adrenocortical carcinoma.

Artikel i vetenskaplig tidskrift
Författare Håkan Ahlman
Amir Khorram-Manesh
Svante Jansson
Bo Wängberg
Ola Nilsson
C E Jacobsson
Sven Lindstedt
Publicerad i World journal of surgery
Volym 25
Nummer/häfte 7
Sidor 927-33
ISSN 0364-2313
Publiceringsår 2001
Publicerad vid Institutionen för laboratoriemedicin
Institutionen för laboratoriemedicin , Avdelningen för patologi
Institutionen för de kirurgiska disciplinerna, Avdelningen för kirurgi
Sidor 927-33
Språk en
Länkar dx.doi.org/10.1007/s00268-001-0031-...
Ämnesord Adrenal Cortex Neoplasms, drug therapy, Adrenocortical Carcinoma, drug therapy, Antineoplastic Agents, therapeutic use, Cisplatin, therapeutic use, Doxorubicin, therapeutic use, Etoposide, therapeutic use, Humans, Mitotane, therapeutic use
Ämneskategorier Kirurgi

Sammanfattning

Adrenocortical carcinoma (ACC) is a rare, aggressive tumor that is often detected in an advanced stage. Medical treatment with the adrenotoxic drug mitotane has been used for decades, but critical prospective trials on its role in residual disease or as an adjuvant agent after surgical resection are still lacking. The concept of a critical threshold plasma level of the drug must be confirmed in controlled studies. Because individual responsiveness cannot be predicted, the use mitotane is still advised for nonresectable disease. In case of cortisol or other steroid overproduction, several drugs (e.g., ketoconazole or aminoglutethimide) may be used. Chemotherapy with single agents (e.g., doxorubicin or cisplatin) have been disappointing, with low response rates (< 30%) and a short response duration. Part of this refractoriness may be explained by the fact that ACC tumors express the multidrug-resistance gene MDR-1. Chemotherapy with multiple agents has been tested in smaller series and has resulted in significant side effects. The best results were achieved by the combination of etoposide, doxorubicin, and cisplatin associated with mitotane, achieving a response rate of 54%, including individual complete responses. To be able to make progress in treating advanced ACC disease, adjuvant multicenter trials must be encouraged. When mitotane-based therapies are used, monitored drug levels are mandatory.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?